Seagen quietly doles out cell therapy patent rights, but scope remains unclear
On the heels of its $43 billion buyout by Pfizer, Seagen is slimming its cell therapy efforts.
The big biotech signed a licensing deal with Gracell Biotechnologies last week, granting the smaller partner rights to certain patents, SEC documents show. Gracell will conduct preclinical and clinical research on the unnamed cell therapy programs and be able to bring up to five to the market.
The scope of Thursday’s deal and content of the Seagen patents, however, remain a mystery for now. Neither company issued a press release about the deal and no financial terms were disclosed in the SEC filings. Representatives for Seagen and Gracell did not immediately respond to requests for comment.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 163,900+ biopharma pros reading Endpoints daily — and it's free.